Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets

Detalles Bibliográficos
Autores principales: Jack, Dominic, Nolting, Axel, Galazka, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450262/
https://www.ncbi.nlm.nih.gov/pubmed/32919180
http://dx.doi.org/10.1016/j.msard.2020.102469
_version_ 1783574780337717248
author Jack, Dominic
Nolting, Axel
Galazka, Andrew
author_facet Jack, Dominic
Nolting, Axel
Galazka, Andrew
author_sort Jack, Dominic
collection PubMed
description
format Online
Article
Text
id pubmed-7450262
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-74502622020-08-27 Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets Jack, Dominic Nolting, Axel Galazka, Andrew Mult Scler Relat Disord Correspondence The Authors. Published by Elsevier B.V. 2020-11 2020-08-27 /pmc/articles/PMC7450262/ /pubmed/32919180 http://dx.doi.org/10.1016/j.msard.2020.102469 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Jack, Dominic
Nolting, Axel
Galazka, Andrew
Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets
title Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets
title_full Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets
title_fullStr Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets
title_full_unstemmed Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets
title_short Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets
title_sort favorable outcomes after covid-19 infection in multiple sclerosis patients treated with cladribine tablets
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450262/
https://www.ncbi.nlm.nih.gov/pubmed/32919180
http://dx.doi.org/10.1016/j.msard.2020.102469
work_keys_str_mv AT jackdominic favorableoutcomesaftercovid19infectioninmultiplesclerosispatientstreatedwithcladribinetablets
AT noltingaxel favorableoutcomesaftercovid19infectioninmultiplesclerosispatientstreatedwithcladribinetablets
AT galazkaandrew favorableoutcomesaftercovid19infectioninmultiplesclerosispatientstreatedwithcladribinetablets

Ejemplares similares